International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 3 , Pages 698-704, 1 July 2011

Patterns of Response After Preoperative Treatment in Gastric Cancer

Presented in part at the 50th Annual Meeting of the American Society for Radiation Oncology, September 21–25, 2008, Boston, MA.

  • Juan A. Díaz-González, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
    • Corresponding Author InformationReprint requests to: Juan A. Díaz-González, M.D., Department of Oncology, Clinica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008. Spain. Tel: (+34) 948-255-400; Fax: (+34) 948-255-500
  • ,
  • Javier Rodríguez, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • José L. Hernández-Lizoain, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Raquel Ciérvide, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Miren Gaztañaga, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Iñigo San Miguel, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Leire Arbea, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • J. Javier Aristu, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Ana Chopitea, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Fernando Martínez-Regueira, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Víctor Valentí, M.D.

      Affiliations

    • Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Jesús García-Foncillas, M.D.

      Affiliations

    • Division of Medical Oncology, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Rafael Martínez-Monge, M.D.

      Affiliations

    • Division of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  • ,
  • Jesús J. Sola, M.D.

      Affiliations

    • Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain

Received 30 December 2009; received in revised form 24 February 2010; accepted 3 March 2010. published online 26 July 2010.

Purpose

To analyze the rate of pathologic response in patients with locally advanced gastric cancer treated with preoperative chemotherapy with and without chemoradiation at our institution.

Methods and Materials

From 2000 to 2007 patients were retrospectively identified who received preoperative treatment for gastric cancer (cT3–4/ N+) with induction chemotherapy (Ch) or with Ch followed by concurrent chemoradiotherapy (45 Gy in 5 weeks) (ChRT). Surgery was planned 4–6 weeks after the completion of neoadjuvant treatment. Pathologic assessment was used to investigate the patterns of pathologic response after neoadjuvant treatment.

Results

Sixty-one patients were analyzed. Of 61 patients, 58 (95%) underwent surgery. The R0 resection rate was 87%. Pathologic complete response was achieved in 12% of the patients. A major pathologic response (<10% of residual tumor) was observed in 53% of patients, and T downstaging was observed in 75%. Median follow-up was 38.7 months. Median disease-free survival (DFS) was 36.5 months. The only patient-, tumor-, and treatment-related factor associated with pathologic response was the use of preoperative ChRT. Patients achieving major pathologic response had a 3-year actuarial DFS rate of 63%.

Conclusions

The patterns of pathologic response after preoperative ChRT suggest encouraging intervals of DFS. Such a strategy may be of interest to be explored in gastric cancer.

Gastric cancer, Preoperative treatment, Neoadjuvant chemotherapy, Chemoradiotherapy, Pathologic response

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest: J.M. Garcia-Foncillas is a consultant with Roche Pharmaceuticals Division and with Sanofy-Aventis. J.M. Garcia-Foncillas has received research grants from Sanofy-Aventis and from Roche.

PII: S0360-3016(10)00421-9

doi:10.1016/j.ijrobp.2010.02.054

International Journal of Radiation Oncology * Biology * Physics
Volume 80, Issue 3 , Pages 698-704, 1 July 2011